Efficacy and Tolerability of Low-dose Simvastatin and Niacin,Alone and in Combination,in Patients With Combined Hyperlipidemia: A Prospective Trial

Abstract

Background: Combination lipid-lowering therapy may be desirable in patients with elevated low-density lipoprotein cholesterol, high triglycerides, and low high-density lipoprotein cholesterol. This study was conducted to determine the lipid-lowering efficacy of the combination of low-dose simvastatin and niacin in patients with combined hyperlipidemia and low high-density lipoprotein cholesterol.

Methods and Results: In this multicenter, prospective, randomized trial, 180 patients with hyper cholesterolemia and hypertriglyceridernia and/or low high-density lipoprotein cholesterol were randomized to combination simvastatin (10 mg/day) and niacin (0.75 g/day) or to either drug alone for 9 weeks. The dose of niacin was doubled (from 0.75 g/day to 1.5 g/day) in both the combination and niacin arms for the remaining 8 weeks. The combination of simvastatin, 10 mg/day, and niacin, 1.5 g/day, reduced total. low-density lipoprotein, and very low-density lipoprotein cholesterol and triglycerides by 248, 29%, 45%, and 31%, respectively, while increasing high-density lipoprotein cholesterol by 31%. The addition of niacin to simvastatin did not enhance the low-density lipoprotein cholesterol-lowering effect of simvastatin; however, the combination was more effective than either monotherapy at raising high-density lipoprotein cholesterol and lowering very low-density lipoprotein cholesterol (P <.05). More patients discontinued treatment because of an adverse event in the niacin (P <.03) and combination groups (P =.06) than the simvastatin group.

Conclusions: Treatment of patients with combined hyperlipidemia and/or low high-density lipoprotein with combination low-dose simvastatin and niacin resulted in large reductions in total, low-density lipoprotein, and very low-density lipoprotein cholesterol and increases in HDL cholesterol. Although the combination was well tolerated in the current trial, its safety needs to be evaluated in larger trials of longer duration.

Keywords

hypercholesterolemia HMG-CoA-reductase inhibitor

Get full access to this article

View all access options for this article.

References

Lipid Research Clinics Program . The lipid research clinics coronary primary prevention trial results: Reduction in incidence of coronary heart disease. JAMA 251:351, 1984

Frick MH , Elo O , Haapa K , Heinonen OP , Heinsalmi P , Helo P , et al. Helsinki heart study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317:1237, 1987

The Scandinavian Simvastatin Survival Study Group . Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4s). Lancet 344:1383, 1991

Fievet C , Fruchart JC . HDL heterogeneity and coronary heart disease. Diabetes Metab Rev 7:155, 1991

Buring JE , O'Connor GT , Goldhaber SZ , Rosner B , Herbert PN , Blum CB , et al. Decreased HDL2 and HDL3 cholesterol, apo A-I and apo A-II, and increased risk of myocardial infarction. Circulation 85:22, 1992

Puchois P , Kandoussi A , Fievet P , Foumer JL , Bertrand M , Koren E , et al. Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis 68:35, 1987

Fruchart JC , Alihaud G . Apolipoprotein A-containing lipoprotein particles: Physiological role, quantification, and clinical significance. Clin Chem 38:793, 1992

Expert Panel on Detection. Evaluation. and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel 11). JAMA 269:3015, 1993

Grundy SM . HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 319:24, 1988

10.

Drood JM , Zimetbaum PJ , Frishman WH . Nicotinic acid for the treatment of hyperlipoproteinemia. J Clin Pharmacol 31:641, 1991

11.

Illingworth DR , Stein EA , Mitchel YB , Dujovne CA , Frost PH , Knopp RH . et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. Arch Intern Med 154:1586, 1994

12.

The Coronary Drug Project Research Group . Clofibrate and niacin in coronary heart disease. JAMA 231:360, 1975

13.

Canner PL , Berge KG , Wenger NK , Stamler J , Friedman L , Prineas RJ , et al. Fifteen year mortality in coronary drug project patients: Long-term benefit with niacin. J Am Coll Cardiol 8:1245, 1986

14.

Frick MH , Elo OE , Haapa K , Heinonen OP , Heinsalmi P , Helo P , Huttunen JK . Helsinki heart study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 317:1237, 1987

15.

Grundy SM , Vega GL . Fibric acids: Effects on lipids and lipoprotein metabolism, Am J Med 83(suppl 5B):9, 1987

16.

Gould AL , Rossouw JE , Santanello NC , Heyse JF , Furberg CD . Cholesterol reduction yields clinical benefit: A new look at old data. Circulation 91:2274, 1995

17.

Pierce LR , Wysowski DK , Gross TP . Myopathy and rhabdomyolysis associated with lovastatin-genifibrozil combinaton therapy. JAMA 263:71, 1990

18.

Tobert JA . Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 62:28J, 1988

19.

McKenney JM , Proctor JD , Harris S , Chinchili VM . A comparison of the efficacy and toxic effects of sustained-versus immediate-release niacin in hypercholesterolemic patients. JAMA 271:672, 1991

20.

Knopp RH , Ginsberg J , Albers JJ , Hoff C , Ogilvie JT , Warnick GR , et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: Clues to mechanism of action of niacin. Metabolism 34:542, 1985

21.

National Cholesterol Education Program Second Annual Report of the Expert Panel On: Detection. evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 89:1329, 1994

22.

Stem RH , Spence JD , Freeman DJ , Parbtani A. Tolerance to nicotinic acid flushing. Clin Pharmacol Ther 50:66, 1991

23.

Counseling the patient with hyperlipidemia. American Heart Association, Bethedesta. MD. Publication 70-061-A, 6-84-50m p. 38-45, 1988

24.

Steiner PM , Freidel J , Bremner WF , Stein EA . Standardization of micromethods for plasma cholesterol, triglyceride, and HDL-cholesterol with the lipid clinics' methodology (abstract). J Clin Chem 19:850, 1981

25.

Myers GL , Cooper GR , Winn CL , Smith SJ . The Centers for Disease Control-National Heart. Lung. and Blood Institute Lipid Standardization Program. An approach to accurate and precise lipid measurements. Clin Lab Med 9:105, 1989

26.

Watnick GR , Albers JJ . A comprehensive evaluation of the heparin manganese precipitation procedure for estimating high-density lipoprotein cholesterol. J Lipid Res 19:65, 1978

27.

Lipid Research Clinics Program. Manual of laboratory operations: Lipid and lipoprotein analysis. Washington. DC: US Dept of Health Education and Welfare. 1982. Publication NIH 75-628

28.

Stein EA , Kreisberg R , Miller V , et al. Effect of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Arch Intern Med 150:341, 1990

29.

Stein EA , DiPersio L , Pesce AJ , et al. Enzyme-linked immunoabsorbent assay of apolipoprotein A-II in plasma using a monoclonal antibody. Clin Chem 32:967, 1986

30.

Miller JA , Stein EA , Kaplan LA . Development of a competitive binding enzyme-linked immunoabsorbent assay (ELISA) for plasma apoprotein E using a monoclonal antibody (Mab). Clin Chem 36:964, 1990

31.

Stein EA , Kumbla L , Miller J , Srivastiva L , Kashyap ML . Development and evaluation of a competitive ELISA for Lp(a). Clin Chem 38:1067, 1992

32.

Parra HJ , Mezdour H , Ghalim N , Bard JM , Fruchart JC . Differential electroimmunoassay of human Lp A-1 lipoprotein particles on ready-to-use plates. Clin Chem 36:1431, 1990

33.

Pun ML . Combining independent one sample tests of significance. Ann Inst Stat Math 19:285, 1967

34.

Jacobson TA , Chin MM , Fromell GJ , Jokubaitis LA , Amorosa LF . Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol 74:149, 1994

35.

Davignon J , Roederer G , Montigny M , Hayden MR , Tan MH , Connelly PW , et al. Comparative efficacy and safety of pravastatin, nicotinic acid, and the two combined in patients with hypercholesterolemia. Am J Cardiol 73:339, 1994

36.

Wahlberg G , Walldius G , Olsson AG , Kirstein P . Effects of nicotinic acid on serum cholesterol concentrations of high density lipoprotein subfractions HDL2 and HDL3 in hyper-lipoproteinaemia. J Intern Med 228:151, 1990

37.

Bard JM , Pam HJ , Camare R , Luc G , Ziegler O , Dachet C , Bruckert E , et al. A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia with particular emphasis on lipoproteins defined by their apolipoprotein composition. Metabolism 41:498, 1992